Genetic screening in sporadic ALS and FTD
Citation:
Turner, M.R. and Al-Chalabi, A. and Chio, A. and Hardiman, O. and Kiernan, M.C. and Rohrer, J.D. and Rowe, J. and Seeley, W. and Talbot, K., Genetic screening in sporadic ALS and FTD, Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 12, 1042-1044Download Item:
Abstract:
The increasing complexity of the genetic landscape in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) presents a significant resource and physician training challenge. At least 10% of those diagnosed with ALS or FTD are known to carry an autosomal dominant genetic mutation. There is no consensus on what constitutes a positive family history, and ascertainment is unreliable for many reasons. However, symptomatic individuals often wish to understand as much as possible about the cause of their disease, and to share this knowledge with their family. While the right of an individual not to know is a key aspect of patient autonomy, and despite the absence of definitive therapy, many newly diagnosed individuals are likely to elect for genetic testing if offered. It is incumbent on the practitioner to ensure that they are adequately informed, counselled and supported in this decision.
Author's Homepage:
http://people.tcd.ie/hardimao
Author: Hardiman, Orla
Type of material:
Journal ArticleCollections
Series/Report no:
Journal of Neurology, Neurosurgery and Psychiatry;88;
12;
Availability:
Full text availableDOI:
http://dx.doi.org/10.1136/jnnp-2017-315995Metadata
Show full item recordLicences: